Clinical Trial Update: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-10-31